Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of CM350 in advanced solid tumors
CTR20220315Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- May 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cm350 in Nonhematologic neoplasms (13 arms), sponsored by Keymed Biosciences. Primary endpoints: Safety assessment, Dose-limiting toxicity and 3 more. Started May 2022; status: active.
02
Drugs
cm350
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220315.